Cargando…
Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies
BACKGROUND: No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer’s disease (AD) and vascular dementia (VD) so far. METHODS: Cox regression models with...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145441/ https://www.ncbi.nlm.nih.gov/pubmed/35624487 http://dx.doi.org/10.1186/s13195-022-01017-4 |
_version_ | 1784716316810149888 |
---|---|
author | Nguyen, Thi Ngoc Mai Chen, Li-Ju Trares, Kira Stocker, Hannah Holleczek, Bernd Beyreuther, Konrad Brenner, Hermann Schöttker, Ben |
author_facet | Nguyen, Thi Ngoc Mai Chen, Li-Ju Trares, Kira Stocker, Hannah Holleczek, Bernd Beyreuther, Konrad Brenner, Hermann Schöttker, Ben |
author_sort | Nguyen, Thi Ngoc Mai |
collection | PubMed |
description | BACKGROUND: No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer’s disease (AD) and vascular dementia (VD) so far. METHODS: Cox regression models with inverse probability of treatment weighting to model the underlying cardiovascular risk were used to assess the associations of low-dose ASA use with all-cause dementia, AD, and VD incidence in community-dwelling older adults from the German ESTHER study (N = 5258) and the UK Biobank (N = 305,394). Inclusion criteria were age of 55 years or older and completed drug assessment. Meta-analyses of the individual participant data from the two prospective cohort studies were performed. RESULTS: Four hundred seventy-six cases of all-cause dementia, 157 cases of AD, and 183 cases of VD were diagnosed over a median of 14.3 years of follow-up in ESTHER. In the UK Biobank, 5584 participants were diagnosed with all-cause dementia, 2029 with AD, and 1437 with VD over a median of 11.6 years. The meta-analysis of both cohorts revealed a weak reduction in hazards for all-cause dementia (hazard ratio (HR) [95% confidence interval (CI)]: 0.96 [0.93 to 0.99]). The strongest protective effect of low-dose ASA was observed in participants with coronary heart disease (CHD) in both cohorts, and a significant interaction was detected. In particular, in meta-analysis, a 31% reduction in hazard for AD, 69% for VD and 34% for all-cause dementia were observed (HR [95% CI]: 0.69 [0.59 to 0.80], 0.31 [0.27 to 0.35], 0.46 [0.42 to 0.50], respectively). Furthermore, compared to non-users, users of low-dose ASA for 10 years or longer (who likely use it because they have CHD or a related diagnosis putting them at an increased risk for cardiovascular events) demonstrated a strong protective effect on all dementia outcomes, especially for VD (HR [95% CI]: 0.48 [0.42 to 0.56]) whereas no protective associations were observed with shorter low-dose ASA use. CONCLUSIONS: The protective potential of low-dose ASA for all-cause dementia, AD, and VD seems to strongly depend on pre-existing CHD and the willingness of patients to take it for a minimum of ten years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01017-4. |
format | Online Article Text |
id | pubmed-9145441 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-91454412022-05-29 Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies Nguyen, Thi Ngoc Mai Chen, Li-Ju Trares, Kira Stocker, Hannah Holleczek, Bernd Beyreuther, Konrad Brenner, Hermann Schöttker, Ben Alzheimers Res Ther Research BACKGROUND: No population-based cohort study investigated a potential inverse association between long-term low-dose acetylsalicylic acid (ASA) use and all-cause dementia and its two most common sub-types Alzheimer’s disease (AD) and vascular dementia (VD) so far. METHODS: Cox regression models with inverse probability of treatment weighting to model the underlying cardiovascular risk were used to assess the associations of low-dose ASA use with all-cause dementia, AD, and VD incidence in community-dwelling older adults from the German ESTHER study (N = 5258) and the UK Biobank (N = 305,394). Inclusion criteria were age of 55 years or older and completed drug assessment. Meta-analyses of the individual participant data from the two prospective cohort studies were performed. RESULTS: Four hundred seventy-six cases of all-cause dementia, 157 cases of AD, and 183 cases of VD were diagnosed over a median of 14.3 years of follow-up in ESTHER. In the UK Biobank, 5584 participants were diagnosed with all-cause dementia, 2029 with AD, and 1437 with VD over a median of 11.6 years. The meta-analysis of both cohorts revealed a weak reduction in hazards for all-cause dementia (hazard ratio (HR) [95% confidence interval (CI)]: 0.96 [0.93 to 0.99]). The strongest protective effect of low-dose ASA was observed in participants with coronary heart disease (CHD) in both cohorts, and a significant interaction was detected. In particular, in meta-analysis, a 31% reduction in hazard for AD, 69% for VD and 34% for all-cause dementia were observed (HR [95% CI]: 0.69 [0.59 to 0.80], 0.31 [0.27 to 0.35], 0.46 [0.42 to 0.50], respectively). Furthermore, compared to non-users, users of low-dose ASA for 10 years or longer (who likely use it because they have CHD or a related diagnosis putting them at an increased risk for cardiovascular events) demonstrated a strong protective effect on all dementia outcomes, especially for VD (HR [95% CI]: 0.48 [0.42 to 0.56]) whereas no protective associations were observed with shorter low-dose ASA use. CONCLUSIONS: The protective potential of low-dose ASA for all-cause dementia, AD, and VD seems to strongly depend on pre-existing CHD and the willingness of patients to take it for a minimum of ten years. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13195-022-01017-4. BioMed Central 2022-05-28 /pmc/articles/PMC9145441/ /pubmed/35624487 http://dx.doi.org/10.1186/s13195-022-01017-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Nguyen, Thi Ngoc Mai Chen, Li-Ju Trares, Kira Stocker, Hannah Holleczek, Bernd Beyreuther, Konrad Brenner, Hermann Schöttker, Ben Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
title | Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
title_full | Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
title_fullStr | Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
title_full_unstemmed | Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
title_short | Long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and Alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
title_sort | long-term low-dose acetylsalicylic use shows protective potential for the development of both vascular dementia and alzheimer’s disease in patients with coronary heart disease but not in other individuals from the general population: results from two large cohort studies |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9145441/ https://www.ncbi.nlm.nih.gov/pubmed/35624487 http://dx.doi.org/10.1186/s13195-022-01017-4 |
work_keys_str_mv | AT nguyenthingocmai longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT chenliju longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT trareskira longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT stockerhannah longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT holleczekbernd longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT beyreutherkonrad longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT brennerhermann longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies AT schottkerben longtermlowdoseacetylsalicylicuseshowsprotectivepotentialforthedevelopmentofbothvasculardementiaandalzheimersdiseaseinpatientswithcoronaryheartdiseasebutnotinotherindividualsfromthegeneralpopulationresultsfromtwolargecohortstudies |